Sonja Brun

Sonja Brun is a Senior Principal Scientist at Pfizer, where they leverage their extensive knowledge in cancer research and pharmacology. They possess a strong background in developing genetically engineered mouse models and patient-derived xenografts to identify key tumor regulators and therapeutic targets. Sonja has previously worked as a Postdoctoral Research Associate at the Salk Institute for Biological Studies and held various positions at Pfizer, advancing through roles from Senior Scientist to Principal Scientist. With a PhD in Pharmacology from Duke University, Sonja has demonstrated expertise in in vivo pharmacology studies and CRISPR-based gene editing, contributing significantly to advancements in patient outcomes and human health.